Last 320.00 INR
Change Today +0.30 / 0.09%
Volume 3.0K
As of 5:12 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

jenburkt pharmaceuticals (JBP) Snapshot

Open
317.20
Previous Close
319.70
Day High
324.20
Day Low
317.20
52 Week High
11/12/14 - 390.20
52 Week Low
03/14/14 - 86.50
Market Cap
1.5B
Average Volume 10 Days
21.6K
EPS TTM
13.37
Shares Outstanding
4.6M
EX-Date
09/3/14
P/E TM
23.9x
Dividend
5.10
Dividend Yield
1.59%
Current Stock Chart for JENBURKT PHARMACEUTICALS (JBP)

Related News

No related news articles were found.

jenburkt pharmaceuticals (JBP) Related Businessweek News

No Related Businessweek News Found

jenburkt pharmaceuticals (JBP) Details

Jenburkt Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations and healthcare products in India and internationally. It primarily offers prescription medicines across various therapeutic areas, such as anti-arthritic, antimalarials, anti-osteoporotic, antibiotics, antidiabetics, anti-inflammatory drugs, gastro intestinal, dermatological, aphrodisiac, anti-ulcerant drugs, anti-hypertensive, anthelmintics, hematinics, neuropathy, and protein preparation, as well as over-the-counter drugs. The company was founded in 1985 and is based in Mumbai, India.

Founded in 1985

jenburkt pharmaceuticals (JBP) Top Compensated Officers

Chairman, Managing Director, Member of Stakeh...
Total Annual Compensation: 7.8M
Chief Financial Officer, Whole Time Director,...
Total Annual Compensation: 1.3M
Compensation as of Fiscal Year 2014.

jenburkt pharmaceuticals (JBP) Key Developments

Jenburkt Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months December 31, 2014

Jenburkt Pharmaceuticals Ltd. reported unaudited standalone earnings results for the third quarter and nine months December 31, 2014. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 213.392 million against INR 194.838 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 35.096 million against INR 27.689 million a year ago. Profit from ordinary activities before tax was INR 35.902 million against INR 27.041 million a year ago. Net profit for the period was INR 30.154 million or INR 6.49 per basic and diluted share before and after extraordinary items against INR 19.541 million or INR 4.20 per basic and diluted share before and after extraordinary items a year ago. For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 627.725 million against INR 562.68 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 93.454 million against INR 76.337 million a year ago. Profit from ordinary activities before tax was INR 95.734 million against INR 72.465 million a year ago. Net profit was INR 74.111 million or INR 15.94 per basic and diluted share before and after extraordinary items against INR 51.965 million or INR 11.18 per basic and diluted share before and after extraordinary items a year ago.

Jenburkt Pharmaceuticals Ltd., Board Meeting, Jan 27, 2015

Jenburkt Pharmaceuticals Ltd., Board Meeting, Jan 27, 2015. Agenda: To discuss quarterly results.

Jenburkt Pharmaceuticals Ltd. Appoints Devangi Sanjeev Shah as Non-Executive and Independent Director

Jenburkt Pharmaceuticals Ltd. announced that Ms. Devangi Sanjeev Shah has been appointed, subject to consent of the Members, as a non-executive and Independent Director of the Company, for a term of five years i.e. from November 11, 2014 to November 10, 2019, by the Board of Directors at their meeting held on November 11, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JBP:IN 320.00 INR +0.30

JBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JBP.
View Industry Companies
 

Industry Analysis

JBP

Industry Average

Valuation JBP Industry Range
Price/Earnings 15.5x
Price/Sales 1.8x
Price/Book 4.7x
Price/Cash Flow 12.5x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JENBURKT PHARMACEUTICALS, please visit www.jenburkt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.